Ireland's Biopharma Sector Is Now Worth €130 Billion

Ireland is the third-largest pharmaceutical exporter in the world. That is not a projection or an aspiration — it is the current reality of a sector that has been built steadily over six decades and now generates €130 billion in exports annually.

The scale of what has been built in Ireland is frequently underappreciated, even by those working within it. Understanding the full picture matters — for career decisions, for investment context and for anyone assessing the long-term trajectory of the Irish economy.

How Ireland Got Here

The foundations were laid in the 1960s when Ireland made a deliberate strategic decision to open its economy to international industry. Pfizer established operations in Ringaskiddy, Cork. Merck arrived in Ballydine, Tipperary. Over the following decades, the cluster grew — first in small molecule manufacturing, then expanding into biologics, cell and gene therapies and advanced manufacturing technologies.

Today Ireland hosts 25 large-scale biologics facilities and 75 small molecule facilities. Total foreign direct investment in the sector stands at €15 billion. The workforce exceeds 50,000 people directly employed in pharmaceutical and biopharma manufacturing — a number that does not capture the extensive downstream employment in supply chain, professional services, logistics and infrastructure.

Ireland's biopharma industry is forecast to add a further 21,000 jobs by 2027.

What Is Changing in 2026

The sector is undergoing significant transformation. The era of large greenfield construction projects — the major facility builds that defined investment announcements through the 2010s and early 2020s — is giving way to a period of digital transformation and operational modernisation.

Companies that have built their Irish facilities are now investing heavily in automation, AI-enabled manufacturing processes and digital quality systems. The skills in demand in 2026 are not the same as those that were in demand five years ago. Digital, data and automation competencies — combined with deep regulatory and quality expertise — are the combination that employers across the sector are actively seeking.

The BioPharmaChem Ireland Sustainability and Responsible Care Report 2026, published in March, documented a sector that grew pharmaceutical exports 29 per cent to €99.9 billion in 2024 while simultaneously cutting electricity-related carbon dioxide emissions by 30.5 per cent. It is the clearest evidence to date that Ireland's biopharma sector is navigating the sustainability transition without sacrificing growth.

The Tariff Question

The introduction of US pharmaceutical tariffs — and Ireland's specific exposure given its role as a major supplier to the American market — has been the dominant concern for the sector in 2026. The evidence to date suggests Ireland's position has remained resilient. The combination of regulatory compliance reliability, consistent FDA inspection outcomes, established supply chain relationships and the sheer difficulty of replicating Ireland's manufacturing ecosystem elsewhere has meant that the anticipated disruption has, at least in the short term, been less severe than feared.

That resilience is not unconditional. The medium-term trajectory of US pharmaceutical trade policy remains uncertain, and the sector will need to continue demonstrating its strategic value to global parent companies whose investment decisions are ultimately made in boardrooms far from Cork and Limerick.

For Those Considering a Career in Irish Biopharma

The opportunity remains substantial. Quality assurance, regulatory affairs, manufacturing sciences, process engineering and increasingly data and digital roles are all areas of sustained hiring activity across the sector. Regional diversification — investment spreading beyond the traditional Cork and Limerick corridor into Athlone, Dundalk, Shannon and other locations — is creating opportunities outside the major cities.

Ireland's position as the world's third-largest pharmaceutical exporter was not built by accident. It was built by consistent investment in the right infrastructure, the right skills and the right regulatory environment. The next chapter of that story is being written now.